0.08
+8.57%
Close of 9 Nov 2026, in AUD
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Vectus Biosystems
Its shares trade on ASX under the ticker VBS.AX. It has been listed since 23 February 2016. In the fiscal year to 30 June 2025, it reported revenue of A$478,182 and a net loss of A$1.8m. At that date it held total assets of A$782,656 and shareholders' equity of −A$256,622.
Vectus Biosystems Ltd. operates as a drug discovery and development company. The company is headquartered in Rosebery, New South Wales. The company went IPO on 2016-02-23. The firm focuses on medical research and development. The company is engaged in developing a treatment for fibrosis and high blood pressure, which includes the treatment for diseases in the fibrotic market, namely heart, kidney, and liver diseases. Its compound, VB0004, focuses on treating the hardening of functional tissue and high blood pressure. The company also focuses on developing candidates for the treatment of fibrotic liver diseases, including non-alcoholic steatohepatitis (NASH) as well as pulmonary fibrotic diseases. The firm has also developed technology focused at improving the speed and accuracy of measuring the amount of deoxyribonucleic acid (DNA) and ribonucleic acid (RNA) in samples tested in laboratories. Accugen is a platform, developed by its wholly owned subsidiary, Accugen Pty Limited, comprising of reagents, and software that quantitate polymerase chain reaction (qPCR) reactions.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Health Care
- Industry
- Biotechnology
- Listed since
- 23 Feb 2016
- Website
- vectusbiosystems.com.au ↗
Leadership
Pay as last reported
- Dr. Ronald ShnierNon-Executive Independent Chairman of the BoardA$100,833
- Mr. Maurie StangNon-Executive Deputy Chairman of the BoardA$55,000
- Mr. Robert WaringCompany Secretary
- Ms. Linda WaltersNon-Executive Director
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 0
- Environment
- 0
- Social
- 0
- Governance
- 0
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Vectus Biosystems Ltd. focuses on drug discovery for fibrosis and high blood pressure treatments.
- Accugen platform improves DNA and RNA measurement speed and accuracy in laboratories.
- VB0004 compound targets hardening of functional tissue and high blood pressure diseases.
Weaknesses
- Vectus Biosystems Ltd. has a limited product portfolio with only one compound in development.
- The company's focus on fibrotic diseases may restrict market expansion opportunities.
- Accugen platform is dependent on laboratory testing applications only.
Opportunities
- Expanding NASH treatment market offers growth potential for Vectus Biosystems Ltd.
- Pulmonary fibrotic diseases represent a new market segment for the company.
- Accugen platform can be adopted by more laboratories for DNA and RNA quantitation.
Threats
- Competition in the fibrosis treatment market may impact Vectus Biosystems Ltd.'s market share.
- Regulatory challenges could delay the development of VB0004 compound.
- NASH treatment market competition is intensifying with new entrants.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.